Chlamydia suis-specific antibody ELISA (indirect) with high specificity and sensitivity
Our Chlamydia suis-specific ELISA has the following advantages:
- easily applicable for routine analysis
- acceptable cost for swine producers
- can be used to support the production of Chlamydia suis sero-negative pigs/breeding stock
- can be used to prevent venereal transmission by serological monitoring of boars on the farms and in artificial insemination centers
- can be used on human samples
- can detect persistent asymptomatic Chlamydia suis infections
Attenuated vaccines based on Salmonella deletion mutant strains (with defective multi drug resistance (MDR) efflux pump systems)
COLIGO interferes with the attachment of F18+ E coli to the pig’s intestinal epithelium. In vivo results demonstrate it significantly reduces duration of shedding and the quantity of F18+ E coli bacteria that are colonising the intestine and being shed in the environment.
The PRRS-virus can infect the cells via the natural route due to the presence of both sialoadhesin and CD163, the two receptors that are essential for binding, internalization and multiplication
Our technology enables you to check the antigenicity (efficacy) and safety of your inactivated viral vaccine in vitro
We describe monoclonal antibodies that can be used to identify antigenic differences between PCV2 strains
Ostertagia ostertagi is one of the most important gastrointestinal nematodes for cattle worldwide. As Ostertagia ostertagi is present on pasture, all grazing cattle in temperate climate regions are exposed to the parasite
PROVAXS-Ghent University has concluded a partnership agreement with the Swedish veterinary diagnostic company, Boehringer Ingelheim Svanova for the commercial launch of a new ELISA kit. The ELISA was developed at the Laboratory of Parasitology of Professor Jozef Vercruysse at Ghent University
At the Laboratory of Parasitology we we have developed an ELISA test that enables us to measure the exposure of pigs to Ascaris suum. The relevance of such a test for pig production is described in the attached document
Our technology enables controlled transfer of biological compounds through the intestinal (mucosal) barrier
We have developed a codon-optimized, MOMP-based DNA vaccine that significantly protects birds (Psittaciformes) against a high challenge with the zoonotic pathogen Chlamydophila psittaci (Cp psittaci)
The vaccine consists of a combination of NetB and alpha-toxin, both detoxified
We have prepared a purine nucleoside platform based on known and novel sugar- and purine ring scaffolds and demonstrated their ability to act as antiprotozoal agents.
– Novel class of superior Th1 polarizing glycolipids valuable as vaccine adjuvant or adjuvant therapy in oncology
Potent alfa galactosyl ceramide analogues targeting invariant natural killer T-cells (iNKT) for selective boosting of cellular immunity.
We identified SP-B, an endogenous protein, as a key component in lung surfactant that strongly improves lung cell permeability for cytosolic delivery. SP-B, combined with our nanoparticle technology, can be applied to deliver various cargo (such as proteins, drug molecules and siRNA) to pulmonary cells.
To enable low-level light therapy for animals we developed Stretchable Molded Interconnect (SMI) technology taking into account
- the optical, mechanical and thermal properties of materials in the LED engine
- the surrounding textile patch in which the LED-matrix is placed (& which can be washed)
- the device geometry (e.g. correct LED density and sufficient openings for breathability)